Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -2 of 2
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Fludarabine Plus Cyclophosphamide Followed by Zevalin in Non-Follicular Indolent Lymphomas Refractory or Relapsed
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 to 70
Other
EUDRACT 2005-000699-41
NCT00354822
Last Modified:
1/7/2009
 
First Published:
1/22/2008
2.
Phase II Randomized Study of Fludarabine Phosphate and Rituximab With Versus Without Lenalidomide or Cyclophosphamide in Patients With Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Biomarker/Laboratory analysis, Treatment
Active
18 and over
NCI
CALGB-10404
CALGB 10404, ECOG-10404, NCIC-CTG-C10404, SWOG-C10404, NCT00602459
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute